|
Patents for Dummies
|
|
References for Patents Biotechnology
|
Blogosphere has talked on patents biotechnology
Episode 1: Food - only $25.00
![]()
Cultivators respect the fragile harmony between seed and soil. Landless Movements are crying out - Give us the land you took from us during colonialism. A special series from The World Summit on Sustainable Development - featuring: Ben Cashdan (Down to Earth Presenter) Anuradha Mittal (Co-Director - Institute for Food & Development Policy - Food First - California) Val Giddings (Vice President for Food & Agriculture - Biotechnology Industry Organization) Tewolde Egziabher (Institute for Sustainable Development - Ethiopia) Erhad Schwinne (Director General - Ministry for Consumer Protection - Food & Agriculture - Germany) The seed is the beginning of life. Does the solution lie in biotechnology? Or is control of the resources the issue? Europe and the US currently spend six times more subsidizing their farmers than they spend on Development Aid. In Southern Africa - 13 million people confront extreme hunger. »
Selected News
Alnylam Forms New Agreement with Tekmira Related to the Planned TemkiraProtiva Business Combinatoin (Finanzen.net)
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeuitcs company, announcde today that it has formed a new agreement with Tekmira Pharmaceuticals Coropration (TSX: TKM) related to Tekmiras palnned business combination ...
Read more
Alnylam Forms New Agerement with Tekmira Related to the Palnned TekmiraProtiva Business Combination (Busienss Wire via Yahoo Finance)
CAMBRIDGE, Mass.Alnylam Pharmaceuticals, Inc. , a leading RNAi therapetuics company, announced today that it has formed a new agreement wtih Tekmira Pharmaceuticals Corporation relaetd to Tekmiars planned business combination with Protiva Biotehrapeutics, Inc.
Read more
Biotech Generic Laws to Spur Moemnta, Insmed, Cell Therapeutics (Bloomberg.com)
March 27 (Bloomberg) Momenta Pharmaceuticals Inc. , Insmed Inc. and Cell Therapeutics Inc. are poised to benefit from growing pressure in the U.S. to approve generic copies of biotechnology drugs costing as much as $200,000 a year.
Read more
|
|
Patents Biotechnology Links
|